Reports

Ideas That Generate Results

Global Bi-Specific Antibodies Market Forecast to 2022

Global Bi-Specific Antibodies Market Forecast to 2022

Format :  Adobe Reader (PDF) Upto 24 hour delivery
Publish Date : Aug, 2018| No. of Pages : 80

Share |
 
Please make your selection :
Electronic Access - Single User License
US$ 2500.00
CD-ROM Mail Delivery
US$ 2700.00
Hard Copy Mail Delivery
US$ 2700.00
Electronic Access - Multi-User License
US$ 3500.00
1. Analyst View
 
2. Research Methodology
 
3. Bi-Specific Antibodies – An Introduction
 
4. Global Bi-Specific Antibodies Market Outlook to 2022
    4.1 BLINCYTO
    4.2 Removab
 
5. Bi-Specific Antibodies Pipeline Analysis
    5.1 By Clinical Phase
    5.2 By Indication
    5.3 By Technology
 
6. Market Dynamics
    6.1 Drivers
          6.1.1 Rising Global Cancer Epidemics
          6.1.2 Bi-Specific Antibodies Improving the Targeting Capabilities of Traditional         mAbs
          6.1.3 T-cells in Bi-Specific Antibodies Mediated Immunotherapy
          6.1.4 Increasing Demand for Bi-Specific/Double Barreled Antibodies
    6.2 Challenges
          6.2.1 Production Hurdles in Bi-Specific Antibodies Development
          6.2.2 Regulatory Challenges
 
7. Current Status of Major Bi-Specific Antibodies in Pipeline
    7.1 BLINCYTO/Blinatumomab – Amgen Inc.
    7.2 ABT-122 – AbbVie Inc.
    7.3 MCLA-128 – Merus N.V.
    7.4 ALX-0761/M1095 - Ablynx
    7.5 MGD006/S80880 – MacroGenics, Inc.
    7.6 ZW25 – Zymeworks Inc.
 
8. Trends and Developments
    8.1 Bi-specific Antibody Application for Tumor Therapy
    8.2 Bi-specific Antibodies Development Against Myeloma
    8.3 Bi-specific Antibody Agreement with EpimAb Biotherapeutics
    8.4 B-specific Antibody Development against Multiple Ebola viruses
 
9. Strategic Collaborations in the Bi-Specific Antibodies Industry
 
10. Competitive Assessment
      10.1 Amgen Inc.
      10.2 F. Hoffman La Roche Ltd.
      10.3 AbbVie Inc.
      10.4 OncoMed Pharmaceuticals, Inc.
      10.5 Glenmark Pharmaceuticals Limited 
      10.6 Xencor, Inc.
      10.7 MacroGenics, Inc.
      10.8 Aptevo Therapeutics Inc.
      10.9 Ligand Pharmaceuticals, Inc.
      10.10 Regeneron Pharmaceuticals, Inc.
      10.11 Fresenius SE & Co. KGaA
      10.12 Merus N.V.
Not able to find data you are looking for? Ask our Research Analyst.

media citation

get in touch

Please fill-in the information below.